MYC rearrangement	Diffuse Large B Cell Lymphoma	MYC rearrangement	Diffuse Large B Cell Lymphoma	lenalidomide Sensitive: B - Late Trials lenalidomide Sensitive : B	lenalidomide Sensitive: B - Late Trials lenalidomide Sensitive : B
MYC rearrangement	Diffuse Large B Cell Lymphoma	MYC rearrangement	Diffuse Large B Cell Lymphoma	lisocabtagene maraleucel Sensitive: C2 – Inclusion Criteria lisocabtagene maraleucel Sensitive : C2	lisocabtagene maraleucel Sensitive: C2 – Inclusion Criteria lisocabtagene maraleucel Sensitive : C2
MYC rearrangement	Diffuse Large B Cell Lymphoma	MYC rearrangement	Diffuse Large B Cell Lymphoma	Sensitive: C3 – Early Trials Sensitive : C3	Sensitive: C3 – Early Trials Sensitive : C3
MYC rearrangement	Mediastinal B Cell Lymphoma	MYC rearrangement	Mediastinal B Cell Lymphoma	rituximab Sensitive: C3 – Early Trials rituximab Sensitive : C3	rituximab Sensitive: C3 – Early Trials rituximab Sensitive : C3
MYC rearrangement	Follicular Lymphoma	MYC rearrangement	Follicular Lymphoma	Sensitive: C3 – Early Trials Sensitive : C3	Sensitive: C3 – Early Trials Sensitive : C3
MYC rearrangement	Non-Hodgkin’s Lymphoma	MYC rearrangement	Non-Hodgkin’s Lymphoma	Sensitive: C3 – Early Trials Sensitive : C3	Sensitive: C3 – Early Trials Sensitive : C3
MYC rearrangement	Diffuse Large B Cell Lymphoma	MYC rearrangement	Diffuse Large B Cell Lymphoma	INCB57643 Sensitive: D – Preclinical INCB57643 Sensitive : D	INCB57643 Sensitive: D – Preclinical INCB57643 Sensitive : D

MYC rearrangement

Associations